{"id":"tp-58567","type":"article-newspaper","title":"MapLight Therapeutics Posts $0.97 Q3 GAAP Loss Per Share, Beats Estimates","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/58567","datePublished":"2026-11-16T15:47:11.000Z","dateModified":"2026-11-16T15:47:11.000Z","language":"en","abstract":"MapLight Therapeutics, Inc. had $463.4 million in cash, cash equivalents and investments as of Sept. 30.","section":"Business","references":[]}